Coya Therapeutics, Inc. Common Stock (COYA) - Total Liabilities
Based on the latest financial reports, Coya Therapeutics, Inc. Common Stock (COYA) has total liabilities worth $4.03 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See COYA working capital ratio to evaluate short-term liquidity relative to the company's equity base.
Coya Therapeutics, Inc. Common Stock - Total Liabilities Trend (2020–2025)
This chart illustrates how Coya Therapeutics, Inc. Common Stock's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see COYA total asset value.
Coya Therapeutics, Inc. Common Stock Competitors by Total Liabilities
The table below lists competitors of Coya Therapeutics, Inc. Common Stock ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Excel Cell Electronic Co Ltd
TW:2483
|
Taiwan | NT$1.64 Billion |
|
Tesoro Gold Ltd
AU:TSO
|
Australia | AU$1.85 Million |
|
SynAct Pharma AB
ST:SYNACT
|
Sweden | Skr44.13 Million |
|
Kolon Life Science Inc
KQ:102940
|
Korea | ₩295.72 Billion |
|
Seoyon Co Ltd
KO:007860
|
Korea | ₩2.05 Trillion |
|
K N Kenanga Holdings Bhd
KLSE:6483
|
Malaysia | RM6.03 Billion |
|
GaeaSoft Corp
KQ:051160
|
Korea | ₩90.81 Billion |
|
Chime Ball Technology Co Ltd
TWO:1595
|
Taiwan | NT$1.31 Billion |
Liability Composition Analysis (2020–2025)
This chart breaks down Coya Therapeutics, Inc. Common Stock's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See how leveraged is Coya Therapeutics, Inc. Common Stock's balance sheet to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 13.40 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.09 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Coya Therapeutics, Inc. Common Stock's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Coya Therapeutics, Inc. Common Stock (2020–2025)
The table below shows the annual total liabilities of Coya Therapeutics, Inc. Common Stock from 2020 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $6.92 Million | +45.12% |
| 2024-12-31 | $4.77 Million | -15.23% |
| 2023-12-31 | $5.63 Million | -66.49% |
| 2022-12-31 | $16.79 Million | +1361.98% |
| 2021-12-31 | $1.15 Million | +156.84% |
| 2020-12-31 | $447.12K | -- |
About Coya Therapeutics, Inc. Common Stock
Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary therapies to enhance the function of regulatory T cells (Tregs). Its candidate product pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. The company develops COYA 302, a biologic combination for subcutaneou… Read more